Kendall D. American Diabetes Association 2005 Scientific Sessions; June 10-14, 2005; San Diego, CA.

End point Muraglitazar 5 mg plus metformin (n=569)

Pioglitazone 30 mg plus metformin (n=550)

HbA1c difference between study arms

p

Change in HbA1c levels (%)

-1.14 -0.85 0.29 <0.0001

Absolute change in HbA1c levels in the muraglitazar and pioglitazone study arms at week 24

End point Muraglitazar 5 mg plus metformin (n=569)

Pioglitazone 30 mg plus metformin (n=550)

p

Change in triglyceride

levels (%)-28.4 -13.4 <0.0001

Change in HDL cholesterol levels (%)

19.2 13.6 <0.0001

Change in apolipoprotein B levels (%)

-11.8 -6.0 <0.0001

Change in non-HDL cholesterol levels (%)

-5.9 -1.2 <0.0001

Kendall D. American Diabetes Association 2005 Scientific Sessions; June 10-14, 2005; San Diego, CA.

Relative change in lipid parameters from baseline in the muraglitazar and pioglitazone study arms at week 12